Intestinal bacteria found to produce SARS-CoV-2-inhibiting compounds
Researchers have screened bacteria in the gut, finding that Bifidobacteria have inhibitory activity against SARS-CoV-2.
List view / Grid view
Researchers have screened bacteria in the gut, finding that Bifidobacteria have inhibitory activity against SARS-CoV-2.
Researchers have developed a native state mass spectrometry technique to identify inhibitors of the bacterial protein metallo-beta-lactamase.
A National Science and Technology Council and Office for Science and Technology Strategy will be established to aid the UK's scientific industry.
A new mRNA vaccine based on the malaria circumsporozoite protein was shown to elicit a robust immune response in mice.
Lung spheroid cells can act as nanodecoys for the SARS-CoV-2 Spike protein to bind to, according to a new pre-clinical study.
Scientists have used imaging methods and machine learning to understand cellular metabolism at the single-cell level.
Researchers have developed a cross-validation high-throughput screening method to accelerate the identification of SHP2 inhibitors.
Researchers have developed a potential strategy to treat cystic fibrosis, using oligonucleotides to correct certain gene defects.
Scientists say COVID-19 may activate tuberculosis infection, but stem cell-mediated defence mechanisms could be targeted to develop vaccines.
Researchers have developed kidney organoids that resemble the collecting duct system, using ureteric bud progenitor cells.
A new magnetically driven rotary microfilter has been developed to filter particles inside a lab-on-a-chip microfluidic device.
Two groups of infant rhesus macaques received one of two potential COVID-19 vaccines, which were shown to elicit high levels of neutralising antibodies.
Researchers have developed a potential cancer treatment using light from radiopharmaceuticals and polymer nanoparticles to kill cancer cells.
Scientists have found differences in 206 genes between the GRCh38 (hg38) and GRCh37 (hg19) human reference genomes.
Researchers have found that the CDK inhibitor AT7519 could be used to treat pancreatic cancer patients whose tumours are addicted to mutant KRAS.